The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.
Huntington's disease (HD) is a genetic neurodegenerative disorder. Since identification of the disease-causing gene in 1993, a number of genetically modified animal models of HD have been generated. The first transgenic mouse models, R6/1 and R6/2 lines, were established 8 years ago. The R6/2 mice have been the best characterized and the most widely used model to study pathogenesis of HD and therapeutic interventions. In the present review, we especially focus on the characteristics of R6 transgenic mouse models and, in greater detail, describe the different therapeutic strategies that have been tested in these mice. We also, at the end, critically assess the relevance of the HD mouse models compared with the human disease and discuss how they can be best used in the future.
Li
Jia Yi
JY
Neuronal Survival Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund, Sweden. Jia-Yi.Li@med.lu.se
Popovic
Natalija
N
Brundin
Patrik
P
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001519:Behavior; D001522:Behavior, Animal; D001921:Brain / Q000473:pathology; D064987:Cell- and Tissue-Based Therapy; D004195:Disease Models, Animal; D006801:Humans; D006816:Huntington Disease / Q000178:diet therapy* / Q000235:genetics* / Q000473:pathology / Q000523:psychology / Q000628:therapy*; D051379:Mice; D008822:Mice, Transgenic / Q000502:physiology*; D011480:Protease Inhibitors / Q000627:therapeutic use; D017510:Protein Folding; D011503:Transglutaminases / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D011480:Protease Inhibitors; D011503:Transglutaminases